EHA-TSH Hematology Tutorial on Lymphoma

Dates: April 6-7, 2019TSH Logo en
Location: İzmir, Turkey

EHA in close collaboration with the Turkish Society of Hematology are organizing the 8th hematology Tutorial. The Tutorial is part of the Turkish School of Hematology, a training program for Turkish fellows in hematology.

Goal of the meeting

This two-day meeting aims to educate Turkish Hematology fellows on Lymphoma diagnosis and treatment in detail.

Target audience

Hematology fellows from Turkey.

Program

The following topics will be covered:

  • The history of lymphoma classification and 2016 WHO revision
  • Role of PET in staging and treatment of lymphomas
  • Follicular Lymphoma: Diagnosis and Treatment (First Line and Relapsed Disease)
  • DLBCL and Double Hit Lymphoma : Diagnosis and Treatment (First Line and Relapsed Disease)
  • Mantle Cell Lymphoma: Diagnosis and Treatment (First Line and Relapsed Disease)
  • Hodgkin Lymphoma: Diagnosis and Treatment (First Line and Relapsed Disease)
  • Systemic T-cell Lymphoma: Diagnosis and Treatment (First Line and Relapsed Disease)
  • Immune check points and cellular therapies for the management of lymphomas

 

Registration

Registration for the EHA-TSH Tutorial is restricted to Turkish hematology fellows who are Turkish Society of Hematology members. For information regarding this tutorial and TSH membership, please contact [email protected].

EBAH CME Accreditation

EBAH accredited stamp DEF2Tutorials are accredited by the European Board for Accreditation in Hematology (EBAH) CME. EBAH CME is the best way for hematologists to master the latest developments within the specialty of hematology. Staying abreast of these scientific developments and keeping in touch with the up-to-date views on clinical policy will enable you to raise your professional level, ultimately resulting in the best treatment for your patients.

Related articles on HemaSphere

  • Immune Checkpoint Inhibition in HL Read more >
  • New treatment options in advanced stage follicular lymphoma Read more > 
  • Controversies in the treatment of CHL Read more >
  • Treatment and survival of patients with primary effusion lymphoma in The Netherlands Read more >